LLY Stock Recent News

Eli Lilly's two weight loss drugs have become blockbusters, bringing in more than $1 billion in annual revenue. Demand is growing in this market, but so is competition.

Eli Lilly And Co LLY is one of several companies benefitting from demand for weight loss drugs. The company is also seeing competition in the market including knockoff drugs that it said could be unsafe.

Steven E. Orr says people are getting healthier, and the accessibility of weight loss drugs from companies like Eli Lilly (LLY) and Novo Nordisk (NVO) make them attractive for investors. However, he warns against Mag 7 stocks, instead pointing to commodities like Gold (/GC) and Silver (/SI).

Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.

Artificial intelligence offers not only huge opportunities in technology but also in healthcare. Novo Nordisk and Hippocratic AI are both striving to developing new pathways.

Monthly EGBLYSS maintenance dosing sustained clear or almost-clear skin for up to three years in the vast majority of ADvocate 1 and 2 responders Nearly 87 percent of patients taking EBGLYSS did not require either high-potency topical corticosteroids or systemic treatments during the three-year study The safety profile at three years was consistent with the previously published two-year results INDIANAPOLIS , Sept. 25, 2024 /PRNewswire/ -- More than 80 percent of adults and adolescents with moderate-to-severe atopic dermatitis who responded to EBGLYSS™ treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials and continued treatment for up to three years experienced sustained skin clearance with monthly maintenance dosing.

Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's CEO and the demand for weight-loss drugs.

Eli Lilly's long-term growth prospects have been secured by the improved supply in H2'24 and the incoming capacity additions from H1'25 onwards. This is on top of the introduction of its D2C channel for self-pay patients, with it offering the company a new growth opportunity through the uninsured patients. This is also why LLY does not appear to be expensive at current levels, with the FWD PEG non-GAAP ratio of 1.30x, well below its historical levels and sector peers.

Eli Lilly has become a household name thanks to breakthrough diabetes and obesity care medicines. The stock has trounced the broader market over the past year, and shares have become a bit pricey.

Netflix and Eli Lilly lead this weekend's list of five stocks near buy points that are all enjoying rapid sales growth.